1021175-71-2

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-Cyano-vinylaMino)-Malonicaciddiethylester is used as a building block for the synthesis of pharmaceuticals due to its ability to contribute to the creation of biologically active compounds. Its structural features make it a valuable component in the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(2-Cyano-vinylaMino)-Malonicaciddiethylester is used as a precursor in the synthesis of various agrochemicals, potentially enhancing crop protection and yield through the development of novel compounds.
Used in Materials Science:
2-(2-Cyano-vinylaMino)-Malonicaciddiethylester is utilized in materials science for the preparation of new materials with specific properties, leveraging its unique chemical structure to create innovative materials for various applications.
Used in Medicinal Chemistry Research:
As a potential enzyme inhibitor, 2-(2-Cyano-vinylaMino)-Malonicaciddiethylester is used in medicinal chemistry research for drug development. Its capacity to inhibit certain enzymes makes it a promising candidate for therapeutic applications, particularly in the discovery of new treatments for various diseases.
Used in Organic Synthesis:
2-(2-Cyano-vinylaMino)-Malonicaciddiethylester is employed as a key intermediate in organic synthesis, where it serves as a versatile building block for the preparation of a wide range of chemical compounds, highlighting its importance in the synthesis of complex organic molecules.

Upstream product

• 6162-76-1 cyanoacetaldehyde 
• 13433-00-6 diethyl aminomalonate hydrochloride 
• 6829-40-9 aminomalonic acid diethyl ester 
• 76064-23-8 3-hydroxyacrylonitrile sodium salt 
• 2407-68-3 3-dimethylaminoacrylonitrile 
• 288-14-2 ISOXAZOLE 

Downstream Products

• 1006609-47-7 ethyl 3-(6-methoxy-7-(3-(4-phenylpiperazin-1-yl)propoxy)quinazolin-4-ylamino)-1H-pyrrole-2-carboxylate 
• 1006609-38-6 ethyl 3-(7-methoxy-6-(3-(4-phenylpiperazin-1-yl)propoxy)quinazolin-4-ylamino)-1H-pyrrole-2-carboxylate 
• 252932-49-3 3-amino-2-ethoxycarbonylpyrrole hydrochloride 
• 1614228-74-8 (R)-ethyl-3-(2-(4-(tert-butoxy)-3,4-dioxo-1-phenylbutan-2-yl)hydrazinyl)-1H-pyrrole-2-carboxylate 
• 1614228-81-7 ethyl 3-(3-(4-(tert-butoxy)phenyl)-2-((tert-butoxycarbonyl) amino) propanamido)-1H-pyrrole-2-carboxylate 
• 1614228-89-5 3-(3-(4-(tert-butoxy)phenyl)-2-((tert-butoxycarbonyl)amino)propanamido)-1H-pyrrole-2-carboxylic acid 
• 1614228-97-5 3-(4-hydroxybenzyl)-3,4-dihydropyrrolo[3,2-e][1,4]diazepine-2,5(1H,6H)-dione 
• 1448695-71-3 4-chloro-7-iodo-5H-pyrrolo[3,2-d]pyrimidine 
• 5655-01-6 3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one 
• 5655-01-6 9-deazahypoxanthine 
• 252932-48-2 3-amino-2-ethoxycarbonylpyrrole 

Relevant academic research and scientific papers

Novel Substituted Purine Isosteres: Synthesis, Structure-Activity Relationships and Cytotoxic Activity Evaluation

A number of pyrrolo[2,3-c]pyridines, pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines were designed and synthesized as antiproliferative agents. The target compounds possessed selected substituents in analogous positions on the central scaffold th

PROCESS FOR THE PREPARATION OF VERDIPERSTAT

An improved process for preparing verdiperstat is disclosed. The process includes the steps of reacting a compound having formula or a salt thereof, wherein R is the same or different and is each independently a C1-C5 alkyl with 3-(dimethylamino)acrylonitrile to obtain a compound having formula; and converting the compound having formula to verdiperstat.

Synthesis and reactivity of pyrrolo[3,2-d][1,3]oxazine-2,4-dione. Access to new pyrrolo[3,2-e][1,4]diazepine-2,5-diones

A convenient synthesis of pyrrolo[3,2-d][1,3]oxazine-2,4-dione 4 is described and its reactivity towards various nucleophiles studied. The regioselective ring opening of anhydride 4 or its N-alkylated analog 25 in the presence of alanine or proline afforded, respectively, imidazolidinedione 22 and N-protected pyrrolo[3,2-e][1,4]diazepines 30 and 31 in a one-pot process. In a last part of this study, an alternative route to produce a library of eight non protected pyrrolo[3,2-e][1,4]diazepine-2,5-diones 35a-h is described to overcome the limited reactivity of anhydride 4.

HETEROCYCLIC COMPOUNDS AND METHODS OF USE

Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Design, synthesis, and in vitro antitumor activity evaluation of novel 4-pyrrylamino quinazoline derivatives

Here, we describe the design and synthesis of two series of 4-pyrrylamino quinazolines as new analogs of the epidermal growth factor receptor inhibitor gefitinib. In vitro antitumor activity of these novel compounds against pancreatic (Miapaca2) and prostate (DU145) cancer cell lines was evaluated. Compared with the parental gefitinib, all 18 derivatives show a greatly increased cytotoxicity to cancer cells. In vitro kinase inhibitory activity on epidermal growth factor receptor was also investigated. Among them, compounds GI-6, GII-4, GII-6, GII-8, and GII-9 are more potential receptor tyrosine kinase (RTK) inhibitors. Based on these results, we propose simple structure-activity relationship to provide information for designing and developing more potent antitumor agents.